Literature DB >> 17720893

Screening for and managing diabetic retinopathy: current approaches.

Zachary T Bloomgarden1.   

Abstract

PURPOSE: The anatomy of the eye and the pathogenesis, clinical features, and prevalence of vision impairment from diabetic retinopathy are described. Screening and risk factors for and treatment of diabetic retinopathy also are addressed.
SUMMARY: The macula and fovea play a critical role in vision. Several interrelated biochemical pathways involving aldose reductase, advanced glycation end products, and protein kinase C link chronic hyperglycemia with retinal capillary endothelial cell damage and dysfunction in patients with diabetic retinopathy. Vision loss and blindness from diabetic retinopathy usually are the result of vascular leakage or ischemia. Screening for retinopathy should be performed within three to five years after the onset of type 1 diabetes and shortly after the diagnosis of type 2 disease, with annual follow-up examinations in both types of diabetes. In patients with diabetic retinopathy, severe vision impairment is less common and less readily corrected than mild vision impairment, and vision impairment is more common and less readily corrected in elderly patients with diabetes than in younger diabetics. Modifiable risk factors for diabetic retinopathy include A1C level, hypertension, cigarette smoking, and dyslipidemia. Tight control of blood glucose concentrations and blood pressure can reduce the risk for and progression of diabetic retinopathy. Aspirin therapy and smoking cessation also are recommended. Dyslipidemia in patients with diabetes is associated with retinopathy progression and vision loss. Treatment of dyslipidemia provides cardiovascular benefits in patients with diabetes, but whether it provides vision benefits remains to be determined. Laser photocoagulation therapy reduces the risk of vision loss in patients with diabetic macular edema, severe nonproliferative diabetic retinopathy, or proliferative diabetic retinopathy. Intraocular surgery may be used for patients with vitreous hemorrhage and retinal detachment of the macula.
CONCLUSION: Therapeutic approaches used for patients with or at risk for diabetic retinopathy include drug therapy to reduce modifiable risk factors, laser photocoagulation, and intraocular surgery. Screening plays an important role in early detection and intervention to prevent the progression of diabetic retinopathy.

Entities:  

Mesh:

Year:  2007        PMID: 17720893     DOI: 10.2146/ajhp070331

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  19 in total

1.  Chronic optic disc swelling overlooked in a diabetic patient with a devastating outcome.

Authors:  Tasanee Braithwaite; Gordon T Plant
Journal:  BMJ Case Rep       Date:  2010-03-23

Review 2.  Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology.

Authors:  Min K Song; Basil D Roufogalis; Tom H W Huang
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 3.  Diabetic retinopathy and pregnancy.

Authors:  Nicola Pescosolido; Orazio Campagna; Andrea Barbato
Journal:  Int Ophthalmol       Date:  2014-01-31       Impact factor: 2.031

4.  The α7-nicotinic acetylcholine receptor and MMP-2/-9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells.

Authors:  Aaron M Dom; Adam W Buckley; Kathleen C Brown; Richard D Egleton; Aileen J Marcelo; Nancy A Proper; Donald E Weller; Yashoni H Shah; Jamie K Lau; Piyali Dasgupta
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-22       Impact factor: 4.799

Review 5.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

6.  Maternal immune system adaptation to pregnancy--a potential influence on the course of diabetic retinopathy.

Authors:  Snježana Kaštelan; Martina Tomić; Josip Pavan; Slavko Orešković
Journal:  Reprod Biol Endocrinol       Date:  2010-10-21       Impact factor: 5.211

7.  Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.

Authors:  Celina García; Jorge Aranda; Edith Arnold; Stéphanie Thébault; Yazmín Macotela; Fernando López-Casillas; Valentín Mendoza; Hugo Quiroz-Mercado; Hebert Luis Hernández-Montiel; Sue-Hwa Lin; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

8.  Safety and efficacy of selective retina therapy (SRT) for the treatment of diabetic macular edema in Korean patients.

Authors:  Young Gun Park; Jae Ryun Kim; Seungbum Kang; Eric Seifert; Dirk Theisen-Kunde; Ralf Brinkmann; Young-Jung Roh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-23       Impact factor: 3.117

9.  Prevalence of diabetic retinopathy in Tehran province: a population-based study.

Authors:  Mohammad Ali Javadi; Marzieh Katibeh; Nasrin Rafati; Mohammad Hossein Dehghan; Farid Zayeri; Mehdi Yaseri; Mojtaba Sehat; Hamid Ahmadieh
Journal:  BMC Ophthalmol       Date:  2009-10-16       Impact factor: 2.209

10.  Prevalence and incidence of retinopathy in elderly diabetic patients receiving early diagnosis and treatment.

Authors:  Xin Li; Zhaoyan Wang
Journal:  Exp Ther Med       Date:  2013-03-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.